Navigation Links
Gene Marker May Improve Odds of Stem Cell Therapies for Disease
Date:1/9/2009

PHILADELPHIA, Jan. 9 /PRNewswire-USNewswire/ -- A single tumor-suppressor gene may provide a unique marker for senescence in Mesenchymal stem cells (MSCs) in vitro, while also playing a role in moving MSCs into senescence, researchers at the Human Health Foundation and the Sbarro Institute for Cancer Research and Molecular Medicine report. Their work was published in Stem Cells and Development.

The finding is important, since MSCs are currently being tested in cell and gene therapy for a number of human diseases.

When injected into the body, MSCs have the unique ability to differentiate into a variety of cells. But before they can be employed for therapeutic uses, the stem cells must be cultivated in vitro. During this process, MSCs are often compromised when they enter senescence, or aging, which limits their capacity to proliferate and differentiate into new tissues, making them useless for treatment.

In the current study, researchers studied senescent MSCs drawn from rats in vitro. MSCs in senescence showed a downregulation, or decrease, in several genes involved in stem cell self-renewal and DNA repair, including Rb1 and p107 gene expression.

However, pRB2/p130, a tumor suppressor gene first identified by Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at the College of Science and Technology at Temple University and a "Chiara Fama" Professor at the University of Siena, Italy, and a co-author of the paper, became the prominent RB protein.

"By studying the process of senescence in MSCs we have arrived at new possibilities to improve the therapeutic capabilities of the stem cells in transplantation," said Giordano.

"The presence of Rb2 during senescence raises the possibility it may provide an early marker of the process," said co-author Umberto Galderisi, a Professor at the University of Naples and an Adjunct Associate Professor at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University. "Next we will work to confirm our data by seeing the impact when Rb2 is silenced in these stem cells."

The Human Health Foundation (HHF) (www.hhfonlus.org) is a nonprofit organization designed to develop and fund biomedical research in Italy. Along with developing new medical research centers, HHF promotes and supports novel methods for the prevention, diagnosis and treatment of cancer and other illnesses; implements and designs new initiatives to exchange and spread the results of new research; and design original programs to inform and increase public awareness of health and research issues.

Sbarro Health Research Organization (www.shro.org), a leader in cancer, cardiovascular, and diabetes research, a nonprofit charitable organization, supports the Sbarro Institute for Cancer Research and Molecular Medicine located at Temple University in Philadelphia.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE Sbarro Health Research Organization
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
2. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
3. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
4. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
5. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. Gene Hunters Fine-Tune Marker for Common Obesity Gene
10. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
11. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, Belmar ... The reputable clinic will continue to be co-owned and managed ... of four clinicians. Lipkin received his doctorate in physical therapy ... of experience with a strong background in manual therapy. ... clinic in and around the Denver ...
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and ... driving up healthcare costs and threatening outcomes, were problems ... supply and IVD industry that support them, met this ... market researcher said that drugs of abuse, procalcitonin and ... sessions at the organization,s 69th meeting in ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... Blue Health Intelligence (BHI) announced today that Dr. Alan Spiro joined ... 30 years of clinical, healthcare IT, value-based care, and change management experience to BHI ... am thrilled to welcome Dr. Spiro to BHI,” said Swati Abbott, CEO of Blue ...
(Date:8/16/2017)... ... ... Any Lab Test Now® is thrilled to announce its groundbreaking ... 36th annual Inc. 5000 , the most prestigious compilation of the nation's fastest-growing ... the American economy’s most dynamic segment — its independent small and midsized businesses. , ...
(Date:8/16/2017)... KS (PRWEB) , ... August 16, 2017 , ... ... latest beneficiary of their recently launched community enrichment program. Partnering once again with ... the KC Superstar competition to help find the area’s very own American Idol. ...
(Date:8/16/2017)... ... ... A global leader in the treatment of clubfoot, CURE International India ... the country one step closer to eliminating clubfoot as a lifelong disability by 2030. ... to enroll 10,000 children in the clubfoot treatment program in this year alone. , ...
(Date:8/16/2017)... ... August 16, 2017 , ... Harbor Retirement Associates (HRA), a ... that two of their associates were recognized with individual “Best of the Best” ... in Florida. The awards were announced at the 5th Annual 2017 Conference, held ...
Breaking Medicine News(10 mins):